Stroke Circulatory System
Conditions
Interventions
The study will take place in two stages.
Stage 1: Observing current arm therapy at each of our research sites
In the first stage, we will look at the current stroke rehabilitation services at 8 NHS i
Sponsors
James Paget University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Sites delivering clinical services to stroke survivors 2. Therapists delivering upper limb therapy to stroke survivors 3. Stroke survivors meeting the following criteria: 3.1. A stroke (ischaemic or hemorrhagic) in adults aged above 18 years 3.2. Have at least a little movement of the upper limb impairment but not have full dexterity; for example,they are able to lift their arm from their lap and place it on a table in front of them but are unable to independently do up small buttons. 3.3. Can navigate the NeuroVirt device independently OR have a family member/carer/healthcare worker who will help with wearing the device. 3.4. Have at least a weak Wi-Fi connection at their home if recruited in the community rehabilitation.
Exclusion criteria
Exclusion criteria: Stroke survivors: 1. Other neurological diagnoses including spinal stroke. 2. Communication,cognitive and language deficits,such as being unable to follow a one-stage command and providing informed consent. 3. Frozen shoulder or other impairments affecting the movement of their arm,such as arthritis or dislocation. 4. Any episode of photosensitive epilepsy within the last 12 months. 5. Presence of cerebral shunts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will use an implementation framework (RE-AIM framework) to measure how well NeuroVirt is working, this has five constructs, and we will use the first four to measure success of our implementation: RE-AIM framework: 1. Reach (how many stroke survivors use NeuroVirt): At least 60% of patients should follow the prescribed NeuroVirt exercises. 2. Effectiveness (does NeuroVirt have an impact?): 60% of patients should show improvement in the game metrics recorded by NeuroVirt. 3. Adoption (are therapists prepared to use NeuroVirt in their clinical practice): 80% of therapists should say they would continue using NeuroVirt after the study. This will be ascertained through focus groups. 4. Implementation (consistent with the protocol): At least 80% of sites should follow the proper steps/adherence to the protocol when using NeuroVirt during the study. This will be measured by site surveys throughout the trial. Additionally, participants will also complete the following outcome measures: Phase 1: 1.EQ5D-5L: as a self-rated measure of health-related quality of life; collected at baseline and discharge from the hospital 2.Arm Activity Measure (ArmA): to evaluate difficulties in both passive and active upper limb function; collected at baseline and at discharge Phase 2: 1.EQ5D-5L: as a self-rated measure of health-related quality of life; collected at baseline and discharge from the hospital 2.Arm Activity Measure (ArmA): to evaluate difficulties in both passive and active upper limb function; collected at baseline and at discharge 3.USEQ (User Satisfaction Evaluation Questionnaire): to evaluate how satisfied are the users who are receiving virtual rehabilitation systems (NeuroVirt), collected at the end of phase 2 | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Contacts
Public ContactKathryn Mares
Outcome results
None listed